Tanushree Shenoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tanushree Shenoy has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Alan Ashworth
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
94 shared publications - Felix Y. Feng
Department of Radiation Oncology, University of California San Francisco , San Francisco, CA
94 shared publications - Michelle L. Badura
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California
85 shared publications - Jonathan Chou
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, USA
69 shared publications - Anil Parsram Bidkar
Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA
60 shared publications - Bradley A. Stohr
Department of Pathology University of California San Francisco San Francisco California USA
60 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 1 shows sgRNA validation and MHCI protein expression on tumor cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 1 shows sgRNA validation and MHCI protein expression on tumor cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Table S1: List of top 20 significant (p< 0.05) genes from a whole-genome CRISPRi FACS-based screen which increased or decreased MHC Class I expression upon knockdown. Genes that were indicated as common essential by DepMap were removed from this list. Table S2A. GSEA Pathway analysis from datasest in Figure 2I (day 28). Table S2B. GSEA Pathway analysis from datasest in Figure 2I (day 49). Table S2C. GSEA Pathway analysis from datasest in Figure 2I (day 91). Table S3. Number of motifs 10kbp from MHC Class I processing genes that were targeted by a small library CRISPR screen. Table S4A. GSEA Pathway analysis from dataset in Figure 4A. Table S4B. GSEA Pathway analysis from dataset in Figure 4A. Table S5A. GSEA Pathway analysis from dataset in Figure 4B. Table S5B. GSEA Pathway analysis from dataset in Figure 4B. Table S6: List of sgRNA sequences. Table S7: List of qRT-PCR primer sequences.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Table S1: List of top 20 significant (p< 0.05) genes from a whole-genome CRISPRi FACS-based screen which increased or decreased MHC Class I expression upon knockdown. Genes that were indicated as common essential by DepMap were removed from this list. Table S2A. GSEA Pathway analysis from datasest in Figure 2I (day 28). Table S2B. GSEA Pathway analysis from datasest in Figure 2I (day 49). Table S2C. GSEA Pathway analysis from datasest in Figure 2I (day 91). Table S3. Number of motifs 10kbp from MHC Class I processing genes that were targeted by a small library CRISPR screen. Table S4A. GSEA Pathway analysis from dataset in Figure 4A. Table S4B. GSEA Pathway analysis from dataset in Figure 4A. Table S5A. GSEA Pathway analysis from dataset in Figure 4B. Table S5B. GSEA Pathway analysis from dataset in Figure 4B. Table S6: List of sgRNA sequences. Table S7: List of qRT-PCR primer sequences.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 5 provides in vivo validation of enhanced T cell responses and enhanced tumor control after AR knockdown.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 5 provides in vivo validation of enhanced T cell responses and enhanced tumor control after AR knockdown.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 3 shows validation of AR binding in MHC regulatory genes of interest +/- AR inhibition with enzalutamide.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 3 shows validation of AR binding in MHC regulatory genes of interest +/- AR inhibition with enzalutamide.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 7 is a graphical abstract of how AR regulates MHCI expression in prostate tumor cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 7 is a graphical abstract of how AR regulates MHCI expression in prostate tumor cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 6 shows clinical data analysis of neoadjuvant androgen axis inhibition in primary prostate cancer as well as expression analysis of AR, MHCI, and IFNG activity in mHSPC clinical samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 6 shows clinical data analysis of neoadjuvant androgen axis inhibition in primary prostate cancer as well as expression analysis of AR, MHCI, and IFNG activity in mHSPC clinical samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 2 demonstrates MHC expression following pharmacologic inhibition of AR and/or ligand withdrawal.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 2 demonstrates MHC expression following pharmacologic inhibition of AR and/or ligand withdrawal.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 4 shows a co-culture of tumor-antigen specific T cell mediated killing of tumor cells +/- AR inhibition or MHCI inhibition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 4 shows a co-culture of tumor-antigen specific T cell mediated killing of tumor cells +/- AR inhibition or MHCI inhibition.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
FigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
FigureS6 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS6 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer